Clinical Trials Logo

Clinical Trial Summary

Pegylated Liposomal Doxorubicin as well as Carboplatin have been showed efficacy in monotherapy as in combination therapy of gynaecologic tumours. As there is no common standard in the therapy of recurrent ovarian carcinoma, tumours of the uterus nor for non-epithelial ovarian tumours at time of designing of this study, this trial shall evaluate the new and well tolerated combination therapy consisting of Pegylated Liposomal Doxorubicin and Carboplatin.


Clinical Trial Description

Aim of these study is the evaluation of combination chemotherapy in a patient subset with gynecologic tumours on regard to tolerance and efficacy. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00189410
Study type Interventional
Source AGO Study Group
Contact
Status Completed
Phase Phase 2
Start date June 2003
Completion date September 2006

See also
  Status Clinical Trial Phase
Completed NCT03676101 - Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 1
Recruiting NCT06416696 - Toripalimab for High-risk Locally Advanced Cervical Cancer Phase 2
Completed NCT01097252 - Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer Phase 3
Recruiting NCT06349148 - The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients N/A
Completed NCT01047345 - A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ (V503-006) Phase 3
Completed NCT00943722 - A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Phase 3